rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Promotes New Blood Vessel and Tissue Growth Better Than Standard Ulcer Drugs

RPEP-005601999Sikiric, P; Separovic, J; Anic, T; Buljat, G; Mikus, D; Seiwerth, S; Grabarevic, Z; Stancic-Rokotov, D; Pigac, B; Hanzevacki, M; Marovic, A; Rucman, R; Petek, M; Zoricic, I; Ziger, T; Aralica, G; Konjevoda, P; Prkacin, I; Gjurasin, M; Miklic, P; Artukovic, B; Tisljar, M; Bratulic, M; Mise, S; Rotkvic, I
Animal StudyPreliminary evidence
The takeaway

BPC-157 stimulated new blood vessel formation and granulation tissue growth more effectively than H2-blockers, omeprazole, or sucralfate, explaining its superior wound healing properties.

Outperformed all

BPC-157 promoted more angiogenesis and granulation tissue than standard ulcer drugs H2-blockers, omeprazole, and sucralfate

What the researchers found

BPC-157 promoted significantly more angiogenesis and granulation tissue formation than H2-blockers, omeprazole, or sucralfate, identifying its primary healing mechanism as enhanced new tissue growth rather than acid suppression.

Why it matters

Understanding that BPC-157 heals by growing new blood vessels and tissue — not just reducing acid — explains why it works across different organ systems, not just the stomach.

How the study worked

Animal study comparing BPC-157 (IP and IG routes) to ranitidine, omeprazole, and sucralfate for angiogenesis and granulation tissue formation in various ulcer models.

What this study cannot tell us

Animal models of ulcer healing. The specific molecular pathways for BPC-157's angiogenic effect were not fully characterized.

How to read the evidence

Preliminary animal evidence with direct comparative data against established medications, providing clear mechanistic insight.

When this study was published

Published in 1999. BPC-157's angiogenic mechanism has been confirmed in subsequent studies and is now considered central to its multi-organ healing effects.

The bigger picture

Most ulcer drugs work by reducing stomach acid. BPC-157's mechanism — growing new blood vessels and tissue — is fundamentally different and explains its broad healing ability across gut, skin, bone, and muscle.

Questions still open

  • Which angiogenic pathways does BPC-157 activate?
  • Could BPC-157 be combined with acid-reducing drugs for synergistic ulcer healing?
  • Does BPC-157's angiogenic effect explain its bone and muscle healing too?

Common questions

How does BPC-157 heal differently from antacids?
Antacids and drugs like omeprazole reduce stomach acid. BPC-157 heals by growing new blood vessels and tissue directly — a fundamentally different approach that works even in tissues that have nothing to do with stomach acid.
Is angiogenesis safe?
The body naturally uses angiogenesis for healing. BPC-157 appears to promote appropriate wound-healing angiogenesis rather than pathological blood vessel growth, though this distinction needs more research.

Read the original research

The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation.

Journal of physiology, Paris, 93(6), 479-85

View on PubMed ↗

Citation

Sikiric, P; Separovic, J; Anic, T; Buljat, G; Mikus, D; Seiwerth, S; Grabarevic, Z; Stancic-Rokotov, D; Pigac, B; Hanzevacki, M; Marovic, A; Rucman, R; Petek, M; Zoricic, I; Ziger, T; Aralica, G; Konjevoda, P; Prkacin, I; Gjurasin, M; Miklic, P; Artukovic, B; Tisljar, M; Bratulic, M; Mise, S; Rotkvic, I. (1999). The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation.. Journal of physiology, Paris, 93(6), 479-85.